Avelumab in Unresectable/Metastatic, Progressive Neuroendocrine Neoplasms

2020 Year in Review - Neuroendocrine Tumors —January 9, 2021

Combined data from two phase 2 trials indicate that avelumab monotherapy had limited antitumor activity in patients with grade 2/3 neuroendocrine neoplasms (NENs).

To assess the role of immunotherapy in NENs, the phase 2 NET-001 (NCT03278405) and NET-002 trials (NCT03278379) were initiated to investigate the efficacy and safety of the anti–programmed cell death ligand 1 inhibitor avelumab. NET-001 completed accrual of 10 patients; the NET-002 trial, with a planned enrollment of 36 patients, was terminated at its interim analysis because of lack of efficacy. The results of the combined patient cohort enrolled in both trials were reported at the 2020 North American Neuroendocrine Tumor Society Annual Symposium. 

Eligibility criteria included patients with unresectable or metastatic World Health Organization grade 2/3 NENs from a gastroenteropancreatic (GEP) or lung primary, ≤2 prior lines of therapy excluding somatostatin analogs, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2. NET-001 investigated grade 3 poorly differentiated GEP neuroendocrine carcinomas, and NET-002 investigated grade 2/3 well-differentiated GEP neuroendocrine tumors. In both trials, eligible patients received avelumab 10 mg/kg intravenously every 2 weeks for 26 cycles. The primary end point was overall response rate by Response Evaluation Criteria in Solid Tumors version 1.1; secondary end points included progression-free survival (PFS), overall survival (OS), disease control rate (DCR) at 6 months, and toxicity.

In the combined cohort, a total of 27 patients were included, of which 10 patients were enrolled in the NET-001 trial and 17 patients in the NET-002 trial. Of the 27 tumors, 21 were GEP and 6 had lung origin. The median age of the combined cohort was 64 years (range, 37-80 years), 30% of patients had ECOG PS 1 to 2, and 78% of patients had received ≤1 prior lines of therapy. The median Ki67 index was 35% (range, 10%-100%). The median time on treatment was 85 days (7 cycles).

In the 24 patients evaluable for efficacy, no objective responses were achieved; stable disease was achieved in 33% of patients, and 6-month DCR was 21%. The median PFS was 3.3 months (range, 1.2-24.6 months), and median OS was 14.2 months.

In the 25 patients who received ≥1 doses of avelumab and were evaluable for safety, treatment-related adverse events (TRAEs; all grades) occurred in 58% of patients. Three patients had grade 3/4 TRAEs leading to treatment discontinuation, 2 patients with hepatitis and 1 patient with infusion-related reaction.

Based on these results, immunotherapy with single-agent avelumab was associated with limited antitumor activity in patients with grade 2/3 NENs; further studies are needed to evaluate the role of dual immunotherapy or combination with chemotherapy in this patient population.

Source: Chan D, et al. North American Neuroendocrine Tumor Society 2020 Annual Symposium; October 1-3, 2020. Abstract C18.

Related Articles
Neuroendocrine Year in Review Introduction
2020 Year in Review - Neuroendocrine Tumors
CLARINET FORTE Study Results of Lanreotide Autogel in Progressive Pancreatic or Midgut NETs
2020 Year in Review - Neuroendocrine Tumors
Results of the CLARINET FORTE trial showed that lanreotide autogel (LAN) 120 mg at escalating dosing frequency (every 14 days) was associated with promising progression-free survival (PFS) benefit and no new safety issues in patients with progressive pancreatic or midgut neuroendocrine tumors (NETs).
Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms
2020 Year in Review - Neuroendocrine Tumors
Results of a retrospective analysis showed that checkpoint inhibitors as monotherapy had limited clinical benefit in patients with grade 3 neuroendocrine tumors (NETs) or neuroendocrine carcinomas (NECs), and modest benefit when combined with another checkpoint inhibitor or chemotherapy.
Last modified: January 11, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code